Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Adepress (paroxetine) in Generalized Anxiety Disorder

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

The aim of the present work was to study the efficacy of Adepress (paroxetine) in different clinical variants of generalized anxiety disorder (GAD) with consideration of comorbid states. Adepress was used as monotherapy for 42 days. Patients’ status was evaluated using the Hamilton anxiety scale (HAM-A) before treatment and then at weekly follow-ups. A total of 49 patients were included in the study and 45 completed it; mean age was 36.2 ± 8.2 years. Patients were divided into two groups depending on whether their condition was dominated by somatic (24 cases) or cognitive (21) anxiety. Adepress was effective in both isolated GAD and GAD complicated by comorbid mental pathology. When somatic anxiety dominated the structure of GAD, treatment effects with Adepress started at treatment weeks 3–4. GAD with a predominance of cognitive anxiety regressed at 3–6 weeks of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A. S. Avedisova, “Venlafaxine (Velaxin): results of international trials of a III generation antidepressant,” Consilium Medicum, No. 11, No. 14, 3 (2006).

  2. Yu. A. Aleksandrovskii, Borderline Mental Disorders [in Russian], Feniks, Rostov-on-Don, Second Edition (1997).

    Google Scholar 

  3. R. V. Akhapkin, “Use of Plizil (paroxetine) in psychiatric practice,” Psikhiat. Psikhofarmakoter., 10, No. 3, 61–66.

  4. Yu. E. Less, “Generalized anxiety disorder: typology and comorbid states,” Ros. Psikhiat. Zh., No. 2, 40–45 (2008).

  5. S. N. Mosolov, Clinical Use of Contemporary Antidepressants [in Russian], St. Petersburg (1995).

  6. S. N. Mosolov, Basic Psychopharmacotherapy [in Russian], Moscow (1996).

  7. P. V. Morozov, “Treatment of depression and anxiety disorders in contemporary psychiatry,” Psikhiat. Psikhofarmakoter., No. 7, 3 (2005).

    Google Scholar 

  8. A. B. Smulevich, “Antidepressants in general medical practice,” Consilium Medicum, Supplement, 3–7 (2002)

  9. V. O. Chakhava, Yu. E. Less, and Ya. V. Malygin, “Efficacy of Rexetine in patients with generalized anxiety disorder,” Ros. Med. Zh., 15, No. 24, 1860–1866 (2007).

    Google Scholar 

  10. V. O. Chakhava, E. Yu. Less, and R. R. Borukaev, “Efficacy of venlafaxine in anxious depression and generalized anxiety disorder,” Ros. Psikhiat. Zh., No. 2, 85–89 (2007).

    Google Scholar 

  11. O. Brawman-Mintzer, “Pharmacologic treatment of generalized anxiety disorder,” Psychiatr. Clin. North Am., 24, 119–137 (2001).

    Article  PubMed  CAS  Google Scholar 

  12. J. C. Ballenger, J. R. T. Davidson, Y. Lecrubier, et al., “Consensus statement on generalized anxiety disorder from the International Consensus group on Depression and anxiety,” J. Clin. Psychiat., 62, Supplement 11, 53–58 (2001).

    Google Scholar 

  13. A. J. Gelenberg, R. B. Lydiard, R. L. Rudolph, et al., “Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder,” J. Am. Med. Assoc., 283, 3082–3088 (2000).

    Article  CAS  Google Scholar 

  14. D. W. Hedges, F. W. Reimherr, R. E. Strong, et al., “An open trial of nefazodone in adult patients with generalized anxiety disorder,” Psychopharmacol. Bull., 32, No. 4, 671–676 (1996).

    PubMed  CAS  Google Scholar 

  15. R. Hoehn-Saric, D. R. McLeod, and W. D. Zimmerli, “Differential effects of alprazolam and imipramine in generalized anxiety disorder somatic versus psychic symptoms,” J. Clin. Psychiat., 49, 293–301 (1988).

    CAS  Google Scholar 

  16. D. F. Klein, “Delineation of two drug-responsive anxiety syndromes,” Psychopharmacologia, 5, 397–408 (1964).

    Article  PubMed  CAS  Google Scholar 

  17. A. Raj and D. Sheehan, “Antidepressants in the treatment of Generalized Anxiety Disorder,” in: Generalized Anxiety Disorder, D. Nutt, K. Rickels, and D. Stein (eds.), Martin Dunitz Ltd. (2002), pp. 137–152.

  18. K. Rickels, R. Downing, E. Schweizer, and H. Hassman, “Antidepressants for the treatment of generalized anxiety disorder,” Arch. Gen. Psychiat., 50, 884–895 (1993).

    PubMed  CAS  Google Scholar 

  19. P. Rocca, P. Fonzo, M. Scotta, et al., “Paroxetine efficacy in the treatment of generalized anxiety disorder,” Acta Psychiat. Scand., 95, 444–450 (1997).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. V. P. Serbskii State Scientific Center for Forensic Psychiatry, Moscow, Russia

    V. O. Chakhava, F. S. Budtueva & R. R. Borukaev

Authors
  1. V. O. Chakhava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. S. Budtueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. R. Borukaev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. O. Chakhava.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 110, No. 8, pp. 25–29, August, 2010.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chakhava, V.O., Budtueva, F.S. & Borukaev, R.R. Efficacy of Adepress (paroxetine) in Generalized Anxiety Disorder. Neurosci Behav Physi 41, 852–856 (2011). https://doi.org/10.1007/s11055-011-9498-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-011-9498-2

Keywords

Search

Navigation